Results 61 to 70 of about 41,447 (182)
Apoptosis resistance in chronic myelogenous leukemia [PDF]
The chronic myeloid leukemia (CML) is the three-phasemyeloproliferative disorder, dependent on the expression of theoncoprotein Bcr-Abl, which is the product of the reciprocaltranslocation between chromosomes 9 and 22, resulting in thePhiladelphia ...
Fabíola Attié de Castro +4 more
doaj
Occurrence of chronic lymphocytic leukemia in patients with chronic myelogenous leukemia
Chronic lymphocytic leukemia (CLL) is the most common leukemia of adults in the western world and constitutes about 33% of all leukemia′s. The incidence of CLL increases with age and are more common in older population.
Pritish K Bhattacharyya
doaj +1 more source
Key Clinical Message Differentiating chronic myelogenous leukemia in primary blast crisis (CML‐BC) from de novo BCR‐ABL1‐positive acute myeloid leukemia (AML) is a diagnostic challenge with therapeutic consequences.
Cedric Pastoret, Roch Houot
doaj +1 more source
Sudden unilateral visual loss as an initial presentation of chronic myelogenous leukemia
Len V Hua, Salisa K WilliamsPacific University Eye Clinic, Forest Grove, OR, USAAbstract: Leukemia is a cancer of the white blood cells. Many patients with leukemia are unaware of their disease until routine blood work up for other conditions ...
Len V Hua, Salisa K Williams
doaj
Josephine Emole,1 Taiwo Talabi,2 Javier Pinilla-Ibarz1 1Department of Malignant Hematology, 2Moffitt Program for Outreach Wellness Education and Resources, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Abstract: Chronic myelogenous ...
Emole J, Talabi T, Pinilla-Ibarz J
doaj
Hyperviscosity retinopathy from chronic myelogenous leukemia. [PDF]
Kaplan TM, Starr MR, Dalvin LA.
europepmc +1 more source
Leukemia is a serious problem affecting both children and adults, leading to death if left untreated. Leukemia is a kind of blood cancer described by the rapid proliferation of abnormal blood cells.
Mahwish Ilyas +4 more
doaj +1 more source
Supremacy of nanoparticles in the therapy of chronic myelogenous leukemia. [PDF]
Janani G, Girigoswami A, Girigoswami K.
europepmc +1 more source

